Targovax to present at upcoming conferences
Oslo, Norway, 6 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences: 10th European Life Science CEO Forum (hosted by Sachs Associates)Date: 7 March 2017Venue: Hilton Zurich Airport Hotel, Zurich, SwitzerlandPanel discussion time: 11:10 CET - Advances in Immuno-Oncology Therapeutics Panel- Magnus Jäderberg (CMO)